Trial Profile
An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Mavrilimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 19 Jan 2022 This trial has been completed in Slovakia (Date of the global end of the trial : 30-Sep-2015), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 13 Jun 2019 Trail has been completed in UK.